The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a huge mover today! About 1.02M shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 30.57% since April 4, 2016 and is downtrending. It has underperformed by 31.66% the S&P500.
The move comes after 7 months positive chart setup for the $2.58 billion company. It was reported on Nov, 4 by Barchart.com. We have $29.98 PT which if reached, will make NASDAQ:ACAD worth $954.60M more.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage
Out of 5 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. ACADIA Pharmaceuticals has been the topic of 14 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Friday, September 4 by JP Morgan. The rating was downgraded by Leerink Swann on Tuesday, May 3 to “Market Perform”. As per Wednesday, October 19, the company rating was reinitiated by Roth Capital. The rating was upgraded by Piper Jaffray on Friday, January 22 to “Overweight”. Leerink Swann initiated ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Tuesday, October 4 with “Mkt Perform” rating. The stock has “Neutral” rating given by Piper Jaffray on Friday, August 7. Vetr upgraded the shares of ACAD in a report on Monday, August 10 to “Hold” rating. The firm earned “Outperform” rating on Sunday, August 9 by Cowen & Co. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Overweight” rating by Piper Jaffray on Friday, August 7. The firm earned “Neutral” rating on Thursday, August 27 by Piper Jaffray.
According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio fall, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Moreover, North Star has 0.01% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 880 shares. Massmutual Commerce Fsb Adv accumulated 10,201 shares or 0% of the stock. Palisade Cap Ltd Liability Com Nj has 72,062 shares for 0.08% of their US portfolio. Blackrock Institutional Tru Com Na last reported 0.01% of its portfolio in the stock. Aqr Capital Mngmt Limited Liability Corp last reported 15,434 shares in the company. Price T Rowe Assocs Md owns 7.12M shares or 0.05% of their US portfolio. Victory Cap Management holds 0% or 443 shares in its portfolio. Glob X Management Ltd Limited Liability Company accumulated 0% or 244 shares. Glenmede Tru Na holds 568 shares or 0% of its portfolio. Harvey Capital Management, a Florida-based fund reported 352,200 shares. Camarda Ltd accumulated 0.01% or 300 shares. Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 3,174 shares. American reported 2,229 shares or 0% of all its holdings. Moreover, State Of Wisconsin Board has 0.01% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 62,040 shares. State Bank Of New York Mellon last reported 404,944 shares in the company.
Insider Transactions: Since July 11, 2016, the stock had 2 buys, and 1 insider sale for $42.47 million net activity. $32,970 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was bought by HARRIGAN EDMUND. BAKER BROS. ADVISORS LP had bought 1.30 million shares worth $43.00 million. $560,033 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was sold by Baity Glenn on Monday, July 11.
Another recent and important ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news was published by Seekingalpha.com which published an article titled: “Acadia: Market Pricing In A Worst-Case Scenario” on November 03, 2016.
ACAD Company Profile
ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.